文献速递乳腺癌

他莫昔芬代谢物Z-恩多昔芬治疗内分泌难治性转移性乳腺癌女性的首次人体I期研究

First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer.
PubMed 文献 · J Clin Oncol · 2017-08-30

该I期研究评估口服Z-恩多昔芬在内分泌难治性雌激素受体阳性转移性乳腺癌患者中的毒性、最大耐受剂量、药代动力学和临床活性,41例入组、38例可评估最大耐受剂量。剂量递增至160 mg/日因未达最大耐受剂量且恩多昔芬浓度>1,900 ng/mL而停止,总临床获益率为26.3%(95%CI,13.4%至43.1%)。作者认为Z-恩多昔芬可提供不受CYP2D6代谢影响的显著药物暴露、可接受的毒性和有前景的抗肿瘤活性。

要点

  • 38例可评估患者接受20至160 mg/日七个剂量水平的每日一次恩多昔芬。
  • 总临床获益率26.3%(95%CI,13.4%至43.1%),含既往他莫昔芬进展者3例。
  • cfDNA突变者无进展生存较短,中位61天对132天(log-rank P=.046)。

核心结论

  • 在内分泌难治性转移性乳腺癌中,Z-恩多昔芬可提供不受CYP2D6代谢影响的显著药物暴露、可接受的毒性和有前景的抗肿瘤活性。

研究设计与样本

  • 口服Z-恩多昔芬的I期研究,入组内分泌难治性雌激素受体阳性转移性乳腺癌患者。
  • 采用加速滴定直至出现中度或剂量限制性毒性,随后按3+3设计,并在40、80和100 mg/日扩展。
  • 41例入组,38例可评估最大耐受剂量确定;对全部患者血清游离循环DNA及160 mg/日组和扩展组活检组织进行肿瘤DNA测序。

主要发现

  • 既往进展的内分泌方案包括芳香化酶抑制剂(n=36)、氟维司群(n=21)和他莫昔芬(n=15)。
  • 患者接受七个剂量水平(20至160 mg)的恩多昔芬每日一次;因未达最大耐受剂量且恩多昔芬浓度>1,900 ng/mL,剂量递增在160 mg/日停止。
  • 恩多昔芬清除不受CYP2D6基因型影响。
  • 1例患者(60 mg)发生第1周期剂量限制性毒性(肺栓塞)。
  • 总临床获益率(稳定>6个月[n=7]或按RECIST标准部分缓解[n=3])为26.3%(95%CI,13.4%至43.1%),包括既往他莫昔芬进展者(n=3)。

关键数值与推荐

  • 13例患者观察到cfDNA突变(PIK3CA[n=8]、ESR1[n=5]、TP53[n=4]和AKT[n=1]),其无进展生存较短(对比无cfDNA突变者;中位61天对132天;log-rank P=.046)。
  • 在ESR1扩增(肿瘤;80 mg/日)和ESR1突变(cfDNA;160 mg/日)者中观察到临床获益。
  • 比较肿瘤活检与cfDNA,部分突变(PIK3CA、TP53和AKT)未被cfDNA检出,而cfDNA突变(ESR1、TP53和AKT)未被活检检出。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Endoxifen is a tamoxifen metabolite with potent antiestrogenic activity. Patients and Methods We performed a phase I study of oral Z-endoxifen to determine its toxicities, maximum tolerated dose (MTD), pharmacokinetics, and clinical activity. Eligibility included endocrine-refractory, estrogen receptor-positive metastatic breast cancer. An accelerated titration schedule was applied until moderate or dose-limiting toxicity occurred, followed by a 3+3 design and expansion at 40, 80, and 100 mg per day. Tumor DNA from serum (circulating cell free [cf); all patients] and biopsies [160 mg/day and expansion]) was sequenced. Results Of 41 enrolled patients, 38 were evaluable for MTD determination. Prior endocrine regimens during which progression occurred included aromatase inhibitor (n = 36), fulvestrant (n = 21), and tamoxifen (n = 15). Patients received endoxifen once daily at seven dose levels (20 to 160 mg). Dose escalation ceased at 160 mg per day given lack of MTD and endoxifen concentrations > 1,900 ng/mL. Endoxifen clearance was unaffected by CYP2D6 genotype. One patient (60 mg) had cycle 1 dose-limiting toxicity (pulmonary embolus). Overall clinical benefit rate (stable > 6 months [n = 7] or partial response by RECIST criteria [n = 3]) was 26.3% (95% CI, 13.4% to 43.1%) including prior tamoxifen progression (n = 3). cfDNA mutations were observed in 13 patients ( PIK3CA [n = 8], ESR1 [n = 5], TP53 [n = 4], and AKT [n = 1]) with shorter progression-free survival ( v those without cfDNA mutations; median, 61 v 132 days; log-rank P = .046). Clinical benefit was observed in those with ESR1 amplification (tumor; 80 mg/day) and ESR1 mutation (cfDNA; 160 mg/day). Comparing tumor biopsies and cfDNA, some mutations ( PIK3CA, TP53, and AKT) were undetected by cfDNA, whereas cfDNA mutations ( ESR1, TP53, and AKT) were undetected by biopsy. Conclusion In endocrine-refractory metastatic breast cancer, Z-endoxifen provides substantial drug exposure unaffected by CYP2D6 metabolism, acceptable toxicity, and promising antitumor activity.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Goetz MP, Suman VJ, Reid JM, et al. First-in-Human Phase I Study of the Tamoxifen Metabolite Z-Endoxifen in Women With Endocrine-Refractory Metastatic Breast Cancer. J Clin Oncol. 2017. PMID: 28854070. doi:10.1200/JCO.2017.73.3246

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。